Treatment of T2D-induced mice with ASX only slightly improved glucose sensitivity in NTG and APPxhQC mice, but it reversed learning and memory deficits, increased levels of hepatic markers IR-β and p-AKT while reducing others, and increased p-S6rp and p65 levels in the brain of NTG mice. The gene discussed is AKT1; the disease is type 2 diabetes mellitus.